We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 27.50 | 27.00 | 27.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 66.64M | -10.1M | -0.0222 | -12.39 | 125.11M |
From Apr 2019 to Apr 2024
TIDMEKF TIDMTTM
RNS Number : 1097G
EKF Diagnostics Holdings PLC
01 November 2018
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Update regarding AIM admission of RenalytixAI and planned change of EKF's nominated adviser
EKF Diagnostics Holdings plc (AIM: EKF) announces that, further to the announcement on 31 October confirming that Renalytix AI plc ("RenalytixAI") had successfully raised GBP22.25 million in gross proceeds, RenalytixAI will now be admitted to trading on AIM on 6 November 2018. An updated Schedule One announcement is expected to be issued on 2 November 2018.
Participants in the fundraising will be contacted by N+1 Singer, the Company or Link Asset Services to confirm updated settlement instructions.
EKF and N+1 Singer, the Company's current nominated adviser and broker, have agreed that in order to preserve the independence of its nominated adviser, EKF will appoint a new nominated adviser after the admission of RenalytixAI. A further announcement will be made in this regard in due course.
N+1 Singer will continue to act as broker to EKF.
Enquiries: EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Tel: 029 2071 0570 Julian Baines, CEO Richard Evans, FD & COO N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000 Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking) Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About EKF Diagnostics Holdings plc www.ekfdiagnostics.com
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
UPDDFLFBVFFLFBD
(END) Dow Jones Newswires
November 01, 2018 13:30 ET (17:30 GMT)
1 Year Ekf Diagnostics Chart |
1 Month Ekf Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
